Q3 Earnings Forecast for Genmab A/S Issued By HC Wainwright

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Investment analysts at HC Wainwright boosted their Q3 2026 EPS estimates for shares of Genmab A/S in a research report issued to clients and investors on Monday, September 14th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.49 per share for the quarter, up from their prior forecast of $0.37. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.17 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2026 earnings at $0.44 EPS and FY2026 earnings at $1.48 EPS.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, August 6th. The company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%.

A number of other brokerages have also issued reports on GMAB. Guggenheim upped their price target on shares of Genmab A/S from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 7th. TD Cowen upgraded Genmab A/S from a “hold” rating to a “buy” rating and lifted their price target for the company from $32.00 to $43.00 in a research report on Wednesday, July 22nd. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. Truist Financial began coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price target on the stock. Finally, New Street Research set a $43.00 price objective on shares of Genmab A/S in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.50.

Genmab A/S Trading Up 4.6%

Genmab A/S stock opened at $34.15 on Wednesday. Genmab A/S has a one year low of $23.62 and a one year high of $35.43. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. The stock has a market cap of $21.30 billion, a PE ratio of 26.89, a price-to-earnings-growth ratio of 1.84 and a beta of 0.84. The stock has a 50-day moving average of $31.19 and a two-hundred day moving average of $28.32.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership lifted its position in Genmab A/S by 36.6% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock worth $153,324,000 after buying an additional 1,334,919 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Genmab A/S by 26.4% in the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after buying an additional 921,700 shares during the period. First Trust Advisors LP lifted its holdings in shares of Genmab A/S by 84.3% in the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after acquiring an additional 1,126,069 shares during the last quarter. Cibc World Market Inc. lifted its stake in Genmab A/S by 31.2% during the fourth quarter. Cibc World Market Inc. now owns 367,282 shares of the company’s stock worth $11,312,000 after purchasing an additional 87,350 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its stake in Genmab A/S by 14.4% during the 1st quarter. Quantinno Capital Management LP now owns 282,498 shares of the company’s stock worth $7,579,000 after acquiring an additional 35,588 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering, developing and commercializing differentiated antibody-based medicines. The company’s research platforms include technologies designed to create human antibodies and bispecific antibodies that engage the immune system to target cancer and other serious diseases.

Genmab’s products and partnered medicines include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; Kesimpta (ofatumumab) for multiple sclerosis, developed with Novartis; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Pfizer.